Journal of Research in Medical Education & Ethics
  • Year: 2012
  • Volume: 2
  • Issue: 1

Dipeptidyl Peptidase-IV Inhibitors for Diabetes Mellitus

  • Author:
  • Prithpal S Matreja, Jaspreet Kaur, Ashwani K Gupta, Amandeep Singh, P M L Khanna, H P Kayath
  • Total Page Count: 10
  • Page Number: 18 to 27

Department of Pharmacology, Gian Sagar Medical College and Hospital, Ram Nagar, District Patiala-140601, India

*Email: drpsmatreja@yahoo.co.in

Online published on 30 May, 2012.

Abstract

Dipeptidyl peptidase (DPP) IV inhibitors are drugs which prolong the action of Glucagon like peptide-1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP). The DPP IV inhibitors have shown improved glycemic control, and reduction of glycosylated haemoglobin in patients with type-2 diabetes. This group of drug has been used as monotherapy and as adjunct therapy to all antidiabetic drugs. The present review evaluates the concept, therapeutic potential and limitations of DPP IV inhibitors as potential antidiabetic agents.

Keywords

DPP IV inhibitors, Type-2 diabetes, Siltagliptin, Vildagliptin, Saxagliptin, Aloglitpin, Linagliptin, Dutogliptin